Latest News

Phase 3 data support ramucirumab/paclitaxel switch maintenance as a post-induction therapy for patients who are not eligible for immunotherapy.
Ramucirumab Maintenance Combo Shows Benefit in HER2– Gastric/GEJ Cancer

March 17th 2025

Phase 3 data support ramucirumab/paclitaxel switch maintenance as a post-induction therapy for patients who are not eligible for immunotherapy.

Updated Nivolumab Data Solidify Use in Advanced Gastric/GEJ/Esophageal Cancers
Updated Nivolumab Data Solidify Use in Advanced Gastric/GEJ/Esophageal Cancers

March 14th 2025

OSE2101 Plus FOLFIRI Meets OS End Point in Advanced PDAC
OSE2101 Plus FOLFIRI Meets OS End Point in Advanced PDAC

March 12th 2025

Clinicians Consider Identification, Management of RCC Through the Patient’s Eyes
Clinicians Consider Identification, Management of RCC Through the Patient’s Eyes

March 8th 2025

Data from the MATTERHORN trial show a trend towards improved overall survival with the durvalumab combination in gastric and GEJ cancers.
Durvalumab Combo Meaningfully Improves EFS in Advanced Gastric/GEJ Cancer

March 7th 2025

More News